MYELOFIBROSIS
Clinical trials for MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Myelofibrosis drug combo trial halted early
Disease control TerminatedThis study tested whether adding the drug parsaclisib to the standard treatment ruxolitinib could help people with myelofibrosis, a rare bone marrow cancer. It included 252 adults with an enlarged spleen and symptoms. The trial was terminated early, so final results are not avail…
Matched conditions: MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 04:53 UTC
-
New combo therapy aims to shrink spleens and ease symptoms in myelofibrosis patients
Disease control TerminatedThis study tested whether adding the experimental drug parsaclisib to the standard treatment ruxolitinib helps people with myelofibrosis whose spleens and symptoms haven't improved enough on ruxolitinib alone. About 177 adults with different types of myelofibrosis took part. The …
Matched conditions: MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 04:52 UTC
-
Terminated trial tests drug combo for rare bone marrow cancer
Disease control TerminatedThis study tested a combination of two experimental drugs, TQ05105 and TQB3909, in 21 adults with moderate- to high-risk myelofibrosis, a rare bone marrow disorder. The goal was to see if the drugs could safely shrink an enlarged spleen and improve symptoms. The trial was termina…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:51 UTC
-
Cord blood transplant shows promise for tough blood cancers
Disease control TerminatedThis study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It included 200 people and aimed to see how many survived one year after the transplant. The approach is intense and mean…
Matched conditions: MYELOFIBROSIS
Phase: NA • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
Promising combo for advanced blood cancer hits snag: trial ends early
Disease control TerminatedThis study looked at combining two drugs, ruxolitinib and CPX-351, to treat advanced stages of myeloproliferative neoplasms (MPN), a group of blood cancers. The goal was to find the best dose and see if the combo worked better than standard care for patients whose disease had pro…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:57 UTC